Clindamycin/tretinoin

Drug Profile

Clindamycin/tretinoin

Latest Information Update: 24 Jun 2015

Price : $50

At a glance

  • Originator Skinvisible Pharmaceuticals
  • Developer Embil Pharmaceutical; Skinvisible Pharmaceuticals
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acne

Most Recent Events

  • 24 Jun 2015 No recent reports on development identified - Preregistration for Acne in Indonesia, Philippines, Malaysia, Azerbaijan, Kyrgyzstan, Turkmenistan, Uzbekistan, Turkey and Kazakhstan (Topical)
  • 16 May 2008 Clindamycin/tretinoin is available for licensing worldwide (http://www.skinvisible.com)
  • 13 May 2008 Clinical trials in Acne in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top